Skip to content

A Pre-market Study to Evaluate the Performance and Safety of a Skin Preparation Device for Removal of Dry Crusty Skin

A Single-center, Open, Randomized, Non-controlled, Comparative Pre-market Investigation to Evaluate the Performance of a Skin Preparation Device for Removal of Hyperkeratotic Skin

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05356572
Enrollment
26
Registered
2022-05-02
Start date
2022-09-01
Completion date
2023-09-26
Last updated
2023-10-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Actinic Lesion, Hyperkeratosis, Hyperkeratotic Actinic Keratosis, Hyperkeratotic Callus, Hyperkeratotic; Lesion, Keratosis, Actinic, Solar Keratosis/Sunburn

Brief summary

In this clinical one-site investigation the performance and safety of a skin preparation device will be evaluated for removing hyperkeratotic skin prior to further medical treatment. Comfort and pain during skin preparation, as well as performance and safety of device, will be compared to comparators on separate skin areas for every subject.

Interventions

DEVICEInvestigational Skin Preparation Device

Removal of hyperkeratotic skin with Investigational Skin Preparation Device

DEVICEGMDN 47102 / Electrode Skin Abrasive Pad

Removal of hyperkeratotic skin with Abrasive Pad for Skin Preparation

DEVICEUMDNS 13-230 / Biopsy punch (Dermal Curette)

Removal of hyperkeratotic skin with Disposable Dermal Curette

Sponsors

Clinius Ltd
CollaboratorINDUSTRY
Mirka Ltd
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
Yes

Inclusion criteria

* Attending the clinic for treatment of actinic keratosis using daylight photodynamic therapy * Age: 18 - 100 years. * Available for two follow-up visits: two weeks after treatment and 4 months after treatment * Provision of informed consent i.e., subject must be able to understand and sign the patient Information and Consent Form * Subject have been informed on the nature, the scope and the relevance of the study

Exclusion criteria

* Known or suspected allergy/hypersensitivity to phenol formaldehyde * Wound at the skin site to be treated * Documented skin disease at the time of enrollment, as judged by the investigator * Previously enrolled in the present investigation * Inclusion in other ongoing investigations simultaneously that would preclude the subject from participating in this investigation as judged by the investigator * Actinic keratosis treatment obtained within last 6 months * Involvement in the planning and conduct of the clinical investigation (applies to all investigation site staff and third party vendor) * Any subject that according to Medical Research Act, paragraphs 7-10, is deemed unsuitable for study enrolment. * Complications that would increase wound risks if investigational product would be used.

Design outcomes

Primary

MeasureTime frameDescription
Grade of hyperkeratotic skin removalDay 0Sufficient hyperkeratotic skin removal in comparison to comparative methods. The removal of hyperkeratotic skin is assessed visually and by palpation. Removal of hyperkeratotic skin measurement grades: All hyperkeratotic skin removed, Partial hyperkeratotic skin removed, None hyperkeratotic skin removed.

Secondary

MeasureTime frameDescription
Grade of skin irritation / grade of allergic skin reaction14 day follow-upInvestigator assessment of adverse effects on skin in comparison to the comparative methods. Grade of skin irritation: none, mild, moderate, severe. Grade of allergic skin reaction: none, mild, moderate, severe.
Duration of operation time per treated skin areaDay 0Operation time assessed by the mean difference in time per treated skin area to remove the hyperkeratotic skin in comparison to comparative methods.
Presence of actinic keratosisDay 0Presence of actinic keratosis (AK) is measured by number of different grades of AK lesions. Number of different grades of AK lesions: None, Grade I AK lesions, Grade II AK lesions, Grade III AK lesions.
Clearance of actinic keratosis4th month follow-upNumber of different grades of actinic keratosis (AK) lesions are measured: None, Grade I AK lesions, Grade II AK lesions, Grade III AK lesions. Actinic keratosis clearance is assessed as the number of cleared actinic keratosis lesions at 4th month follow-up divided by the actinic keratosis lesion number at Day 0. Clearance will be reported in %. A high %-value means a high number of cleared lesions.
Grade of injury to skin / grade of skin irritation / grade of allergic skin reactionDay 0Investigator assessment of adverse effects on skin in comparison to the comparative methods. Grade of injury to skin: none, mild, moderate, severe. Grade of skin irritation: none, mild, moderate, severe. Grade of allergic skin reaction: none, mild, moderate, severe.
Subject comfort during skin preparation using a subject questionnaireDay 0Rate of subject comfort (including skin sensation and heating of skin) when comparing the investigational product with comparative methods. The endpoint will utilize a questionnaire for the subject to fill in. Skin sensation during skin preparation: Very pleasant, Pleasant, Neutral, Unpleasant, Very unpleasant. Heating of skin during skin preparation: None, Mild temperature rise, Moderate temperature rise, High temperature rise, Burning.
Subject pain sensation during skin preparationDay 0Rate of pain using visual analogue scale (VAS). VAS: 0 - 10 (0= No pain and 10 = worst possible pain)
Subject pain sensation during daylight photodynamic treatmentDay 0Rate of pain using visual analogue scale (VAS). VAS: 0 - 10 (0= No pain and 10 = worst possible pain)
Physician comfort during skin preparation using an investigator questionnaireDay 0Rate of physician comfort when comparing the investigational product versus comparative methods. The endpoint will utilize a questionnaire for the investigator/nurse to fill in.

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026